CO5261510A1 - Inhibidores de aspartil proteasa - Google Patents

Inhibidores de aspartil proteasa

Info

Publication number
CO5261510A1
CO5261510A1 CO00008433A CO00008433A CO5261510A1 CO 5261510 A1 CO5261510 A1 CO 5261510A1 CO 00008433 A CO00008433 A CO 00008433A CO 00008433 A CO00008433 A CO 00008433A CO 5261510 A1 CO5261510 A1 CO 5261510A1
Authority
CO
Colombia
Prior art keywords
alkyl
optionally substituted
alkenyl
carbon atoms
independently selected
Prior art date
Application number
CO00008433A
Other languages
English (en)
Inventor
Michael R Hale
Christopher T Baker
Timothy A Stammers
Ronald G Sherrill
Andrew Spaltenstein
Eric S Furfine
Francois Maltais
Andrews Clarence Webster
John F Miller
Vicente Samano
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of CO5261510A1 publication Critical patent/CO5261510A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/39—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/42—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/18—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un compuesto de fórmula I:<EMI FILE="00008433_1" ID="1" IMF=JPEG >o una sal farmacéuticamente aceptable del mismo, en donde:E' es -CO- o -SO2-;A se selecciona a partir de H; Ht; R1-Ht; -R1-C1-C6 alquilo, el cual esta sustituido opcionalmente con 1 o más grupos independientemente seleccionados de hidroxi , alcoxi con 1 a 4 átomos de carbono, Ht, -O-Ht, -NR2-CO-N(R2)2, -SO2-R2 o -CO-N(R2)2, -R1 alquenilo con 2 a 6 átomos de carbono, el cual es sustituido opcionalmente con 1 o mas grupos independientemente seleccionados de hidroxi, alcoxi con 1 a 4 átomos de carbono, Ht, -O-Ht, -NR2-CO-N(R2)2 o -CO-N(R2)2; o R7; en donde:Cada R1 es independientemente seleccionado a partir de -C(O)-, -S(O)2-, -C(O)-C(O)-, -O-C(O)-, -O-S(O)2, -NR2-S(O)2-, -NR2-C(O)- o -NR2-C(O)-C(O)-;Cada Ht seleccionado independientemente de cicloalquilo con 3 a 7 átomos de carbono, cicloalquenilo con 5 a 7 átomos de carbono; arilo con 6 a 14 átomos de carbono; o un heterociclo no saturado o saturado con 5 a 7 miembros, que contiene 1 o mas heteroátomos seleccionados entre N, O, o S; en donde dicho arilo o dicho heterociclo esta opcionalmente fundido a Q; y en donde cualquier miembro de dicho Ht es opcionalmente sustituido con 1 o mas sustituyentes independientemente seleccionados de oxo, -OR2, SR2, -R2, -N(R2)(R2), -R2-OH, -CN, -CO2R2, -C(O)-N(R2)2, -S(O)2-N(R2)2, -N(R2)-C(O)-R2, -N(R2)-C(O)O-R2, -C(O)-R2, -S(O)n-R2, -OCF3, -S(O)n-Q, metilenedioxi, -N(R2)-S(O)2(R2), halo, -CF3, -NO2, Q, OQ, -OR7, -SR7, -R7, -N(R2)(R7) o -N(R7)2;Cada Q se selecciona independientemente a partir de un sistema de anillo carboxílico parcialmente saturado o no saturado con 3 a 7 miembros saturados; o un anillo heterocíclico parcialmente saturado o no saturado con 5 a - 2 -7 miembros saturados que contiene uno o más heteroátomos seleccionados a partir de O, N, o S, en donde Q es sustituido opcionalmente con 1 o más grupos que seleccionan de oxo, -OR2, -R2, -SO2R2, -SO2-N(R2)2, -N(R2)2, -N(R2)-C(O)-R2, -R2-OH, -CN, -CO2R2, -C(O)-N(R2)2, halo o CF3;Cada R2 se selecciona independientemente de H, o alquilo con 1 a 4 átomos de carbono en donde dicho alquilo, cuando no es un sustituyente de Q, es sustituido opcionalmente con Q o -OR3; en donde cuando dicho R2 es una porción substituida -OR3, dicho R3 en -OR3 puede no ser -OR2 substituido;B, cuando está presente, es -N(R2)-C(R3)2-C(O)-;Cada x es independientemente 0 o 1;Cada R3 es seleccionado independientemente de H, Ht, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-6 o cicloalquenilo C5-6; en donde cualquier miembro de dicho R3, excepto H, es sustituido opcionalmente con uno o más sustituyentes seleccionados a partir de -OR2, -C(O)-NH-R2, -S(O)n-N(R2)(R2), -N(R2)2, -N(R2)-C(O)-O(R2), -N(R2)-C(O)-N(R2), -N(R2)-C(O)-(R2), Ht, -CN, -SR2, -CO2R2, o NR2-C(O)-R2;Cada n es independientemente 1 o 2;G, cuando está presente, se selecciona a partir de H, R7 o alquilo C1-4, o, cuando G es alquilo con 1 a 4 átomos de carbono, G y R7 están opcionalmente ligados uno al otro sea directamente o a través de un ligador con 1 a 3 átomos de carbono para formar un anillo heterocíclico; oCuando G no está presente, el nitrógeno al cual G está ligado se liga directamente al grupo R7 en -OR7 con el desplazamiento concomitante de un grupo -ZM desde R7;D es seleccionado a partir de Q, alquilo C1-6 opcionalmente sustituido con 1 o más grupos seleccionados a partir de cicloalquilo C3-6, -OR2, -S-Ht, -R3, -O-Q o Q; alquenilo con 2 a 4 átomos de carbono sustituido opcionalmente con 1 o más grupos seleccionados a partir de -OR2, -S-Ht, -R3, -O-Q o Q; cicloalquilo C3-6 opcionalmente sustituido con o fundido con Q; o cicloalquenilo C5-6 opcionalmente sustituido con o fundido a Q;D' es seleccionado de alquilo C1-C15, alquenilo C2-C15 o alquinilo C2-C15, cada uno de los cuales contiene uno o más sustituyentes seleccionados de oxo, halo, -CF3, -OCF3, -NO2, azido, -SH, -SR3, - N(R3)-N(R3)2, -O-N(R3)2, -(R3)N-O-(R3), -N(R3)2, -CN, -CO2R, -C(O)-N(R3)2 -S(O)n-N(R3)2, -N(R3)-C(O)-R3, -N(R3)-C(O)-N(R3)2, -N(R3)-C(O)-S(R3)2, -C(O)-R3, -S(O)n-R3, -N(R3)-S(O)n(R3), -N(R3)-S(O)n-N(R3)2, -S-NR3-C(O)R3, -C(S)N(R3)2, - C(S)R3, -NR3-C(O)OR3, -O-C(O)OR3, -O-C(O)N(R3)2, -NR3 C(S)R3, =N-OH, =N-OR3, =N-N(R3)2, =NR3, =NNR3C(O)N(R3)2, =NNR3C(O)OR3, =NNR3S(O)n-N(R3)2, -NR3-C(S)OR3, -NR3-C(S)N(R3)2, -NR3-C[=N(R3)]-N(R3)2, -N(R3)-C[=N-NO2]-N(R3)2, -N(R3)-C[=N-NO2]-OR3, -N(R3)-C[=N-CN]-OR3, N(R3)-C[=N-CN]-(R3)2, -OC(O)R3, -OC(S)R3, -OC(O)N(R3)2, -C(O)N(R3)-N(R3)2, -O-C(O)N(R3)-N(R3)2, O-C(O)N(OR3)(R3), N(R3)-N(R3)C(O)R3, N(R3)-OC(O)R3, N(R3)-OC(O)R3, N(R3)-OC(O)R3, -OC(S)N(R3)2, -OC(S)N(R3)(R3), o PO3-R3; con la condición de que cuando R7 es H, E´ es -SO2, G es H o alquilo, y cuando B esta presente o cuando B no está presente y R1 es -C(O)-, D´ puede no ser alquilo sustituido de 1 a 15 carbonos con un sustituyente seleccionado de -N(R3)2, -SR3 o -S(O)n-R3, o sustituido con dos -N(R3)2 sustituyentes; E se selecciona a partir de Ht; O-Ht; Ht-Ht; Ht fundido con Ht; -O-R3; -N(R2)(R3); alquilo C1-C6 opcionalmente sustituido con uno o más grupos seleccionados a partir de R4 o Ht; alquenilo C2-C6 opcionalmente substituido con 1 o más grupos seleccionados a partir de R4 o Ht; carbociclo saturado con C3-C6 opcionalmente sustituido con o más grupos seleccionados a partir de R4 o Ht; o carbociclo insaturado con C5-C6 opcionalmente sustituido con uno o más grupos seleccionados de R4 o Ht; Cada R4 es seleccionado independientemente a partir de -OR2, -OR3, -SR2, -SOR2, -SO2R2, CO2R2, -C(O)-NHR2, -C(O)-N(R2)2, -C(O)-NR2(OR2), -S(O)2-NHR2, halo, -NR2-C(O)-R2, -N(R2)2 O -CN;Cada R7 es seleccionado independientemente a partir de hidrógeno, <EMI FILE="00008433_2" ID="2" IMF=JPEG > En donde cada M es seleccionado independientemente a partir de H, Li, Na, K, Mg, Ca, Ba, -N(R2)4, alquilo C1-C12, - 3 - alquenilo C2-C12, o -R6; en donde 1 a 4 de los radicales -CH2 del grupo alquilo o alquenilo, diferentes del -CH2 que esta ligado al Z, es reemplazado opcionalmente por un grupo heteroátomo seleccionado a partir de O, S(O), S(O)2, o N(R2); y en donde cualquier hidrógeno en dicho alquilo, alquenilo o R6 es reemplazado opcionalmente con un sustituyente seleccionado a partir de oxo, -OR2, -R2, N(R2)2, N(R2)3, R2OH, -CN, -CO2R2, -C(O)-N(R2)2, S(O)2-N(R2)2, N(R2)-C(O)-R2, C(O)R2, -S(O)n-R2, OCF3, -S(O)n-R6, -N(R2)-S(O)2-(R2), halo, -CF3, o -NO2;M' es H, alquilo C1-C12, alquenilo C2-C12, o R6; en donde los radicales 1 a 4 de -CH2 del grupo alquilo o alquenilo se reemplazan opcionalmente por un grupo de heteroátomos seleccionados a partir de O, S, S(O), S(O)2, o N(R2); y en donde cualquier hidrógeno en dicho alquilo, alquenilo, o R6 es reemplazado opcionalmente con un sustituyente seleccionado a partir de oxo, -OR2, -R2, -N(R2)2, N(R2)3, -R2OH, -CN, -CO2R2, -C(O)-N(R2)2, -S(O)2-N(R2)2, -N(R2)-C(O)-R2, C(O)R2, -S(O)n-R2, OCF3, -S(O)n-R6, -N(R2)-S(O)2-(R2), halo, -CF3, o -NO2;Z es O, S, N(R2)2, o, cuando M no esta presente, H.Y es P o S;X es O o S;R9 es C(R2)2, O o N(R2); en donde cuando Y es S, Z no es S;R6 es un sistema de anillo heterocíclico o carbocíclico saturado o no saturado parcialmente con 5 a 6 miembros saturados, o un sistema de anillo bicíclico parcialmente saturado o no saturado con 8 a 10 miembros saturados; en donde cada uno de dichos sistemas de anillos heterocíclicos contiene uno o más heteroátomos seleccionados a partir de O, N, S, S(O)n o N(R2); y en donde cualquiera de los sistemas de dichos anillos contiene opcionalmente 1 a 4 sustituyentes independientemente seleccionados a partir de OH, alquilo C1-C4, alquilo -O-C1-C4- o alquilo -O-C(O)-C1-C4.
CO00008433A 1999-02-12 2000-02-09 Inhibidores de aspartil proteasa CO5261510A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12004799P 1999-02-12 1999-02-12

Publications (1)

Publication Number Publication Date
CO5261510A1 true CO5261510A1 (es) 2003-03-31

Family

ID=37874715

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00008433A CO5261510A1 (es) 1999-02-12 2000-02-09 Inhibidores de aspartil proteasa

Country Status (4)

Country Link
US (4) US6319946B1 (es)
CO (1) CO5261510A1 (es)
TN (1) TNSN00027A1 (es)
TW (1) TWI260322B (es)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122000A1 (en) * 1981-01-07 2004-06-24 Vertex Pharmaceuticals Incorporated. Inhibitors of aspartyl protease
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
TWI260322B (en) * 1999-02-12 2006-08-21 Vertex Pharma Inhibitors of aspartyl protease
TWI286476B (en) * 2001-12-12 2007-09-11 Tibotec Pharm Ltd Combination of cytochrome P450 dependent protease inhibitors
WO2003057173A2 (en) * 2002-01-07 2003-07-17 Sequoia Pharmaceuticals Broad spectrum inhibitors
US7157489B2 (en) * 2002-03-12 2007-01-02 The Board Of Trustees Of The University Of Illinois HIV protease inhibitors
CN1313472C (zh) * 2002-04-26 2007-05-02 吉里德科学公司 Hiv蛋白酶抑制剂化合物的膦酸酯类似物的细胞蓄积及这类化合物
US20050261237A1 (en) * 2003-04-25 2005-11-24 Boojamra Constantine G Nucleoside phosphonate analogs
WO2005002626A2 (en) * 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
EA014685B1 (ru) 2003-04-25 2010-12-30 Джилид Сайэнс, Инк. Фосфонатсодержащие антивирусные соединения (варианты) и фармацевтическая композиция на их основе
AU2004233897A1 (en) * 2003-04-25 2004-11-11 Gilead Sciences, Inc. Kinase inhibitor phosphonate conjugates
US7470724B2 (en) * 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
CN101410120A (zh) * 2003-04-25 2009-04-15 吉里德科学公司 抗炎的膦酸酯化合物
US7452901B2 (en) * 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
US20090247488A1 (en) * 2003-04-25 2009-10-01 Carina Cannizzaro Anti-inflammatory phosphonate compounds
US7427636B2 (en) * 2003-04-25 2008-09-23 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
WO2004096285A2 (en) * 2003-04-25 2004-11-11 Gilead Sciences, Inc. Anti-infective phosphonate conjugates
US7432261B2 (en) * 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
US7407965B2 (en) * 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
WO2005000249A2 (en) * 2003-06-27 2005-01-06 Smithkline Beecham Corporation Preparation of chemical compounds
US7273715B2 (en) * 2003-10-24 2007-09-25 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds with GS-9005 ester hydrolase A
WO2005044279A1 (en) * 2003-10-24 2005-05-19 Gilead Sciences, Inc. Purine nucleoside phosphonate conjugates
US7432273B2 (en) * 2003-10-24 2008-10-07 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
US20050153990A1 (en) * 2003-12-22 2005-07-14 Watkins William J. Phosphonate substituted kinase inhibitors
BRPI0417988A (pt) * 2003-12-22 2007-04-27 Gilead Sciences Inc análogos de fosfonato antivirais
BRPI0418031A (pt) * 2003-12-22 2007-04-17 Gilead Sciences Inc inibidores de quinase fosfonato-substituìdos
JP2007528423A (ja) * 2004-03-11 2007-10-11 セコイア、ファーマシューティカルズ、インコーポレイテッド 耐性防止レトロウイルスプロテアーゼ阻害薬
JP5073480B2 (ja) 2004-05-07 2012-11-14 セコイア、ファーマシューティカルズ、インコーポレイテッド 耐性防止レトロウイルスプロテアーゼ阻害薬
ATE505196T1 (de) 2004-07-27 2011-04-15 Gilead Sciences Inc Nukleosid phosphonat konjugate als anti hiv mittel
EP2139883A4 (en) * 2007-03-23 2011-06-22 Univ Massachusetts INHIBITORS OF HIV-1 PROTEASE
US8569364B2 (en) 2007-11-28 2013-10-29 Sequoia Pharmaceuticals, Inc. 5-substituted benzofurans as inhibitors of cytochrome P450 2D6
CA2716348C (en) 2008-02-21 2017-04-04 Sequoia Pharmaceuticals, Inc. Diamide inhibitors of cytochrome p450
US20100093667A1 (en) 2008-07-08 2010-04-15 Gilead Sciences, Inc. Salts of hiv inhibitor compounds
EP2723758B1 (en) 2011-06-21 2018-06-20 Alnylam Pharmaceuticals, Inc. Angiopoietin-like 3 (angptl3) irna compostions and methods of use thereof
EP2723390B1 (en) 2011-06-23 2017-12-27 Alnylam Pharmaceuticals, Inc. Serpina1 sirnas: compositions of matter and methods of treatment
EP2726108B1 (en) 2011-06-29 2018-01-10 The Trustees of Columbia University in the City of New York Inhibitor of neuronal connectivity linked to schizophrenia susceptibility and cognitive dysfunction
US9127274B2 (en) 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
WO2014075093A1 (en) * 2012-11-09 2014-05-15 The Trustees Of Columbia University In The City Of New York Inhibitors of central nervous system vasoactive inhibitory peptide receptor 2
JP6574383B2 (ja) 2012-12-05 2019-09-11 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ＰＣＳＫ９ｉＲＮＡ組成物及びその使用方法
PL2970974T3 (pl) 2013-03-14 2018-01-31 Alnylam Pharmaceuticals Inc Kompozycje komponentu C5 dopełniacza iRNA i sposoby ich zastosowania
AP2015008862A0 (en) 2013-05-22 2015-11-30 Alnylam Pharmaceuticals Inc Tmprss6 irna compositions and methods of use thereof
MY176712A (en) 2013-05-22 2020-08-19 Alnylam Pharmaceuticals Inc Serpina1 irna compositions and methods of use thereof
AU2014362262B2 (en) 2013-12-12 2021-05-13 Alnylam Pharmaceuticals, Inc. Complement component iRNA compositions and methods of use thereof
KR102389968B1 (ko) 2014-02-11 2022-04-25 알닐람 파마슈티칼스 인코포레이티드 케토헥소키나제(ＫＨＫ) ｉＲＮＡ 조성물 및 그의 사용 방법
TW201607559A (zh) 2014-05-12 2016-03-01 阿尼拉製藥公司 治療ｓｅｒｐｉｎｃ１相關疾患之方法和組成物
WO2015179724A1 (en) 2014-05-22 2015-11-26 Alnylam Pharmaceuticals, Inc. Angiotensinogen (agt) irna compositions and methods of use thereof
WO2016039403A1 (ja) * 2014-09-11 2016-03-17 塩野義製薬株式会社 持続性ｈｉｖプロテアーゼ阻害剤
WO2016040589A1 (en) 2014-09-12 2016-03-17 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting complement component c5 and methods of use thereof
EP3207138B1 (en) 2014-10-17 2020-07-15 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
WO2016069694A2 (en) 2014-10-30 2016-05-06 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
CN113846101A (zh) 2014-11-17 2021-12-28 阿尔尼拉姆医药品有限公司 载脂蛋白C3（APOC3）iRNA组合物及其使用方法
WO2016130806A2 (en) 2015-02-13 2016-08-18 Alnylam Pharmaceuticals, Inc. Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
CA2982450A1 (en) 2015-04-13 2016-10-20 Alnylam Pharmaceuticals, Inc. Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
AU2016257996A1 (en) 2015-05-06 2017-10-26 Alnylam Pharmaceuticals, Inc. Factor XII (Hageman Factor) (F12), Kallikrein B, Plasma (Fletcher Factor) 1 (KLKB1), and Kininogen 1 (KNG1) iRNA compositions and methods of use thereof
EP3307316A1 (en) 2015-06-12 2018-04-18 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof
WO2016205323A1 (en) 2015-06-18 2016-12-22 Alnylam Pharmaceuticals, Inc. Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
EP3350328A1 (en) 2015-09-14 2018-07-25 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof
KR20180095843A (ko) 2015-12-07 2018-08-28 젠자임 코포레이션 Serpinc1-연관 장애의 치료를 위한 방법 및 조성물
EP3387129A1 (en) 2015-12-10 2018-10-17 Alnylam Pharmaceuticals, Inc. STEROL REGULATORY ELEMENT BINDING PROTEIN (SREBP) CHAPERONE (SCAP) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
EP3469083A1 (en) 2016-06-10 2019-04-17 Alnylam Pharmaceuticals, Inc. COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
TWI788312B (zh) 2016-11-23 2023-01-01 美商阿尼拉製藥公司 絲胺酸蛋白酶抑制因子Ａ１ ｉＲＮＡ組成物及其使用方法
WO2018112320A1 (en) 2016-12-16 2018-06-21 Alnylam Pharmaceuticals, Inc. Methods for treating or preventing ttr-associated diseases using transthyretin (ttr) irna compositions
CA3070319A1 (en) 2017-07-21 2019-01-24 Viiv Healthcare Company Regimens for treating hiv infections and aids
SI3661937T1 (sl) 2017-08-01 2021-11-30 Gilead Sciences, Inc. Kristalinične oblike etil((S)-((((2R,5R)-5-(6-amino-9H-purin-9-IL)-4- fluoro-2,5-dihidrofuran-2-IL)oksi)metil)(fenoksi)fosforil)-L-alaninata (GS-9131) za zdravljenje virusnih okužb
AU2018360697A1 (en) 2017-11-01 2020-05-14 Alnylam Pharmaceuticals, Inc. Complement component C3 iRNA compositions and methods of use thereof
CN112673103A (zh) 2018-08-13 2021-04-16 阿尔尼拉姆医药品有限公司 乙型肝炎病毒(HBV)dsRNA剂组合物及其使用方法
SG11202107669WA (en) 2019-01-16 2021-08-30 Genzyme Corp Serpinc1 irna compositions and methods of use thereof
WO2021154941A1 (en) 2020-01-31 2021-08-05 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4604402A (en) 1984-03-30 1986-08-05 E. R. Squibb & Sons, Inc. Hydroxy substituted ureido amino and imino acids
US4629724A (en) 1984-12-03 1986-12-16 E. R. Squibb & Sons, Inc. Amino acid ester and amide renin inhibitors
DK0656887T3 (da) 1992-08-25 1999-07-05 Searle & Co Hydroxyethylaminosulfonamider til anvendelse som inhibitorer af retrovirale proteaser
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5723490A (en) 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
TW372972B (en) 1992-10-23 1999-11-01 Novartis Ag Antiretroviral acyl compounds
ES2134924T3 (es) 1992-10-30 1999-10-16 Searle & Co Acidos sulfonilalcanoilamino-hidroxietilamino-sulfamicos utiles como inhibidores de proteasas retrovirales.
US5484926A (en) 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
AU7669794A (en) 1993-08-24 1995-03-21 G.D. Searle & Co. Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors
IL110898A0 (en) 1993-09-10 1994-11-28 Narhex Australia Pty Ltd Polar-substituted hydrocarbons
IL111584A0 (en) 1993-11-18 1995-01-24 Merck & Co Inc Prodrugs of an inhibitor of hiv protease and pharmaceutical compositions containing them
US5527829A (en) 1994-05-23 1996-06-18 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
JP4014220B2 (ja) * 1995-01-20 2007-11-28 ジー．ディー．サール アンド カンパニー ビス−スルホンアミドヒドロキシエチルアミノ レトロ ウイルスプロテアーゼインヒビター
US5691372A (en) * 1995-04-19 1997-11-25 Vertex Pharmaceuticals Incorporated Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease
TWI260322B (en) * 1999-02-12 2006-08-21 Vertex Pharma Inhibitors of aspartyl protease

Also Published As

Publication number Publication date
US20040127488A1 (en) 2004-07-01
TWI260322B (en) 2006-08-21
US7442718B2 (en) 2008-10-28
TNSN00027A1 (fr) 2005-11-10
US6319946B1 (en) 2001-11-20
US20090042973A1 (en) 2009-02-12
US7919523B2 (en) 2011-04-05
US6617350B2 (en) 2003-09-09
US20020198388A1 (en) 2002-12-26

Similar Documents

Publication Publication Date Title
CO5261510A1 (es) Inhibidores de aspartil proteasa
CO5160337A1 (es) Inhibidores de aspartilo proteasa proteasa
CO4990992A1 (es) Profarmacos de compuestos de sulfonamida como inhibidores de aspartil proteasa
AR042635A1 (es) Imidazoquinolinas arilsustituidas y composiciones farmaceuticas que las contienen
CO5721006A2 (es) Derivados de pirazolo-quinazolina, proceso para su preparacion y su uso como inhibidores de quinasa
AR117139A1 (es) Derivados de piridooxazinona como inhibidores de monoacilglicerol ligasa (magl)
AR127309A2 (es) Derivados de piridazinona
AR045529A1 (es) Imidazoquinolinas sustituidas con grupos ariloxi o arilalquilenoxi
AR076486A1 (es) Inhibidores de fosfoinositida 3 kinasa y composiciones farmaceuticas que los contienen.
AR107032A1 (es) Inhibidores bicíclicos de pad4
CA2217745A1 (en) Oxygenated-heterocycle containing sulfonamide inhibitors of aspartyl protease
AR088828A1 (es) DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3
PE20241063A1 (es) Composiciones y metodos para la inhibicion de ras
PE20212070A1 (es) Moduladores de trex1
AR083953A1 (es) Compuestos para tratar enfermedades neurodegenerativas
AR059621A1 (es) Acidos 4- fenil- tiazol-5- carboxilicos y amidas de acidos 4- fenil- tiazol5 carboxilicos como inhibidores de la plk1
AR058180A1 (es) Indeno derivados, su preparacion y su uso como medicamentos
CO2020001326A2 (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
AR059520A1 (es) Derivados de ariltienopirimidinonas azaciclil sustituidas,procedimiento para su preparacion,medicamentos que las contienen y usos terapeuticos como antagonistas de receptores mch1r.
AR107030A1 (es) Inhibidores aza-bencimidazol de pad4
AR126053A1 (es) Derivados de triazina
PE20220704A1 (es) Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmaceuticas que los contienen y sus usos como agentes proapoptoticos
AR116905A1 (es) Derivados de ácido pirrolidino-2-carboxílico para tratar el dolor y afecciones relacionadas con el dolor
AR122986A1 (es) Derivados de piridazina como inhibidores de alk5 y/o alk4
PE20230110A1 (es) Procesos para la preparacion de un inhibidor de cinasa

Legal Events

Date Code Title Description
FA Application withdrawn